$25.910
+0.130 (+0.50%)收盤時
AKTS 資訊
AKTS 事件
Aktis Oncology Strong Execution Sets Stage for Data-Rich 2027
"This was a quarter of strong execution for Aktis, focused on generating clinical data and building infrastructure to support our clinical pipeline," said Matthew Roden, President and Chief Executive Officer of Aktis Oncology. "Our AKY-2519 clinical imaging and dosimetry data presented at ASCO generated significant enthusiasm among clinical investigators, helping to advance enrollment in the ongoing Phase 1b trials of AKY-1189 and AKY-2519, and setting the stage for a data-rich 2027."
Aktis Oncology Cash and Securities Reach $538.5 Million
Cash, cash equivalents and marketable securities were $538.5M as of March 31, compared to $226.8M as of December 31, 2025. "We continue to build momentum toward delivering a new class of radiopharmaceuticals targeting tumor types with large patient populations, leveraging our differentiated miniprotein radioconjugate platform and patient-first end-to-end supply chain," said Matthew Roden, President and Chief Executive Officer of Aktis Oncology. "Last week, we announced the initiation of our Phase 1b clinical trial of AKY-2519 in patients with mCRPC. This is the first of two trials in our clinical development strategy designed to expand the breadth of tumors studied and augment speed to data, with preliminary data from the mCRPC trial anticipated in 2027. We plan to initiate a second Phase 1b basket trial of AKY-2519 in additional solid tumors in the second half of this year. We also look forward to presenting our first AKY-2519 clinical imaging and dosimetry data for AKY-2519 at ASCO, which informed our clinical development strategy."
Aktis Oncology Initiates Phase 1b Trial of AKY-25191
Aktis Oncology announced the initiation of a Phase 1b clinical trial of AKY-25191 in patients with metastatic castration-resistant prostate cancer. The mCRPC-dedicated Phase 1b trial is part of Aktis' clinical development strategy to develop AKY-2519 broadly in B7-H3 expressing tumors. Aktis plans to initiate a Phase 1b basket trial in lung, colorectal, and other high B7-H3 expressing solid tumors in the second half of 2026.
Aktis Oncology Appoints Glenn Gormley as Independent Director
Aktis Oncology announced the appointment of Glenn Gormley, MD, PhD, as an independent director to its Board of Directors and co-chair of the Company's newly established Science and Technology Committee of the Board of Directors.
Aktis Oncology Receives FDA Clearance for AKY-25191 to Enter Phase 1b Clinical Trial
Aktis Oncology announced the FDA cleared the investigational new drug applications for the company to proceed to a Phase 1b clinical trial with AKY-25191. AKY-2519 is a miniprotein radioconjugate targeting B7-H3, which is expressed in several solid tumor types including prostate and lung cancers, and is the second clinical stage miniprotein radioconjugate discovered using Aktis' proprietary platform. The company's lead miniprotein radioconjugate, AKY-1189, targeting Nectin-4, is currently enrolling patients in a Phase 1b clinical study. Aktis' miniprotein radioconjugates are designed to selectively deliver actinium-225, a highly potent alpha-emitting radioisotope, to target-expressing tumors. The company also provided business updates and reported financial results for the year ended December 31, 2025.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。